Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 4, 2012, Pages 623-632

  Tyner, J W ^a   Jemal, A M ^a   Thayer, M ^a   Druker, B J ^a,b   Chang, B H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

IAP; RNAi; targeted therapy

Indexed keywords

PROTEIN P53; SEPANTRONIUM BROMIDE; SMALL INTERFERING RNA; SURVIVIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL VIABILITY; CHILDHOOD CANCER; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84859631420     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.249     Document Type: Article

References (33)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243-4251.
2. Bhojwani D, Kang H, Moskowitz N, Min D, Lee H, Potter J et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006; 108: 711-717. (Pubitemid 44061374)
3. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007; 92: 1043-1050. (Pubitemid 350144210)
4. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278: 23130-23140. (Pubitemid 36830379)
5. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-6102. (Pubitemid 30035627)
6. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T et al. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-907. (Pubitemid 38112885)
7. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy. Cancer Treat Rev 2009; 35: 553-562.
8. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24: 1994-2007. (Pubitemid 40520508)
9. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005.
10. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344 (Pt 2): 305-311. (Pubitemid 30011584)
11. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol 2001; 11: 886-890. (Pubitemid 32532816)
12. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10: 1319-1328.
13. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 2002; 13: 3064-3077. (Pubitemid 35034246)
14. Chu Y, Yao PY, Wang W, Wang D, Wang Z, Zhang L et al. Aurora B kinase activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol 2011; 3: 260-267.
15. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA 2009; 106: 8695-8700.
16. Azuara V. Profiling of DNA replication timing in unsynchronized cell populations. Nat Protoc 2006; 1: 2171-2177. (Pubitemid 46773340)
17. Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D et al. Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. J Biol Chem Jan 15; 285: 1850-1860.
18. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127. (Pubitemid 39578701)
19. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021. (Pubitemid 47395135)
20. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-2622. (Pubitemid 34478319)
21. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M et al. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 1992; 6: 42-46.
22. Zhou M, Gu L, Yeager AM, Findley HW. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 1998; 12: 1756-1763. (Pubitemid 28502495)
23. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303: 124-131.
24. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 2000; 95: 1435-1442. (Pubitemid 30099858)
25. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23: 39-48. (Pubitemid 38142238)
26. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006; 107: 1555-1563. (Pubitemid 43242394)
27. Baudis M, Prima V, Tung YH, Hunger SP. ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr Blood Cancer 2006; 47: 757-764. (Pubitemid 44476751)
28. Wang Z, Fukuda S, Pelus L. Survivin regulates the P53 tumor suppressor gene family. Oncogene 2004; 23: 8146-8153. (Pubitemid 39531855)
29. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002; 100: 2463-2471.
30. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001; 32: 119-125. (Pubitemid 32150638)
31. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000; 275: 9102-9105. (Pubitemid 30185122)
32. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011; 102: 614-621.
33. Ryan B, O'Donovan N, Duffy M. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-562.